Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib for Leiomyosarcoma with HR Pathway Alterations
NCT05174455Phase 2Withdrawn
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of niraparib in leiomyosarcoma (LMS). Planned start Dec 2023; status: withdrawn.
02
Drugs
niraparib
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT05174455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174455.